Balyasny Asset Management
SNDX icon

Balyasny Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Balyasny Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,000
Closed -$1.54M – 3515
2025
Q3 		$1.54M Buy
+100,000
New +$1.31M ﹤0.01% 1930

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Balyasny Asset Management's SNDX Position: Q3 2025 in Review

Balyasny Asset Management sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 126,145 shares — an estimated $1.65M sold.

Balyasny Asset Management first reported a position in SNDX in Q4 2017 and held it in 11 quarters. The position peaked at $22.3M in Q1 2025. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • Balyasny Asset Management reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 126,145 Syndax Pharmaceuticals shares in Q3 2025, an estimated $1.65M.
  • Balyasny Asset Management first reported a position in Syndax Pharmaceuticals in Q4 2017 and held it in 11 quarters.
  • Balyasny Asset Management's Syndax Pharmaceuticals position peaked at $22.3M in Q1 2025.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Balyasny Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.